Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

PDEK: pre-Descemet´s endothelial keratoplasty - clinical outcomes

Search Title by author or title

Session Details

Session Title: Cornea: Surgical I

Session Date/Time: Sunday 08/10/2017 | 10:30-12:30

Paper Time: 11:40

Venue: Meeting Center Room I

First Author: : P.Studeny CZECH REPUBLIC

Co Author(s): :    D. Krizova   Y. Klimesova   M. Netukova              

Abstract Details

Purpose:

To present clinical outcomes after PDEK – relatively new type of corneal endothelial transplantation, where the corneal lamella is formed from Dua´s layer, Descemet´s membrane and endothelial cells.

Setting:

Department of Ophthalmology, University Hospital Kralovske Vinohrady, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic

Methods:

68 patients after PDEK, with minimal 6 months follow-up time. We evaluated visual acuity, endothelial cell density (ECD) and frequency of operative and postoperative complications. Part of lamellae was prepared directly by surgeon on the operating theater, part of them was prepared under conditions of tissue bank and subsequently re-evaluated before final use. For separation of stroma and Dua´s layer was user technique big bubble

Results:

The mean uncorrected visual acuity increase from 0,19 ± 0,18 to 0,46 ± 0,31 and corrected distance visual acuity increased (CDVA) from 0,33 ± 0,2 to 0,64 ± 0,27. In subgroup of patients with no other ocular pathology ( n = 33) the CDVA was 0,74 ± 0,24 in average . The ECD 3 months after surgery was 1887 ± 564 cc/mm2 and 1924 ± 627 cc/mm2 in average. The preoperative ECD on donor corneas was 2883 ± 308 cc/mm2 in average. In 31 eyes (45%) we noticed partial detachment of lamellae with re-bubbling.

Conclusions:

PDEK appears to be a safe and effective method for transplantation of corneal endothelium with a low incidence of surgical and postoperative complication

Financial Disclosure:

NONE

Back to previous